Anavex Presents New Data on Preclinical Development of ANAVEX 3-71

Results Demonstrate Significant Reversal in Cognitive Deficit, Inflammation and Alzheimer’s-like Amyloid Pathology NEW YORK, NY – March 14, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various…

Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference

Trial Extension Granted at Request of Patients and Caregivers NEW YORK, NY – March 10, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been requested by…